Press Release

Corporate Office: Solara Active Pharma Sciences Limited TICEL Bio Park, 6th Floor, Module No. 601, 602, 603, Phase II – CSIR Road, Taramani, Chennai, Tamil Nadu – 600113. Tel: +91 44 4344 6700 Fax: +91 44 47406190 E-mail: investors@solara.co.in Website: www.solara.co.in Date: July 23, 2026 The BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Bandra-Kurla Complex Dalal Street, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 541540, 890202 Scrip Code: SOLARA, SOLARAPP1 Dear Sir / Madam, Subject: Press Release Pursuant to the Regulation 30 of the SEBI Listing Regulations, we are enclosing herewith a copy of the Press Release on financial results for the quarter ended June 30, 2026. The same will also be made available on the website of the Company https://solara.co.in/investor-relations/investor-update/ The Press Release (along with Earnings Presentation) for the Board Meeting held on July 23, 2026, issued by the Company titled: Solara reports Strong Q1’27 Base business performance with continued Growth and Profitability This is for your information and records. Thanking You, Yours Faithfully, For Solara Active Pharma Sciences Limited Pooja Jaya Kumar Company Secretary & Compliance Officer ICSI Membership No.: A57415 Solara Active Pharma Sciences Limited - CIN: L24230MH2017PLC291636 Registered Office: 9th Floor, ‘Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703; Tel: +91-22-20870033 Solara reports Strong Q1’27 Base business performance with continued Growth and Profitability Base business (Ex-Ibuprofen): ≫ Q1’27 Base business Revenues at INR 3,077 Mn, up 24% YoY ≫ Q1’27 Base business EBITDA at INR 722 Mn, up 8% YoY ≫ EBITDA was marginally impacted by higher input costs resulting from ongoing geopolitical developments in West Asia. Ibuprofen business: ≫ Q1’27 Ibuprofen business Revenues at INR 765 Mn with an EBITDA loss of INR 87 Mn Overall business: ≫ Q1’27 Overall Revenues at INR 3,843 Mn, up 20% YoY ≫ Q1’27 Overall EBITDA at INR 635 Mn, up 10% YoY; ≫ Q1’27 Overall PAT at INR 163 Mn; marking the highest EBITDA and PAT reported over the last eighteen quarters, reflecting resilient operating performance and continued diligent execution. Solara Active Pharma Sciences Limited | Q1’27 Earnings Update | July 23, 2026 Safe Harbor Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements“. These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Strong start to FY27 with Q1’27 EBITDA at INR 635 Mn and PAT at INR 163 Mn; Highest in the last eighteen quarters Sandeep Rao Managing Director & CEO Q1 FY27 was another quarter of resilient execution. Our overall Revenues stood at INR 3,843 Mn, up 20% YoY; EBITDA at INR 635 Mn, up 10% YoY and PAT at INR 163 Mn, up 55% YoY. This is the highest EBITDA and PAT achieved in the last eighteen quarters. These results underscore the strength of our core business, disciplined execution and our continued focus on profitable growth. Our Base Business continues to exhibit robust momentum, supported by consistent operational execution and a focus on profitable growth. Our Base business Revenues stood at INR 3,077 Mn, up 24% YoY; Gross margins of INR 1,580 Mn, up 10% YoY and EBITDA at INR 722 Mn, up 8% YoY; in spite of input cost pressures resulting from higher raw material prices on account of the ongoing geopolitical developments in West Asia. The sustained performance of the Base business reinforces our confidence in its long-term growth potential. The Commodity Ibuprofen business continues to face profitability challenges, reporting an EBITDA margin of negative 12% amid a difficult operating environment. While profitability remains under pressure, we witnessed a marginal sequential improvement during the quarter. Our ongoing efforts on strengthening the Balance sheet has led to reduction of net debt by INR 1,346 Mn during the quarter bringing our net debt to INR 4,795 Mn, resulting in a Net debt to EBITDA ratio of ~1.9 (annualised). Looking ahead, we remain committed to building on this strong foundation by driving sustainable growth, enhancing margins, and creating long-term value for our stakeholders through disciplined execution, operational excellence, and prudent capital allocation." The Base business delivers strong performance with Revenues of INR 3,077 Mn, up 24% YoY and EBITDA of INR 722 Mn, up 8% YoY, inspite of short-term headwinds related to West Asia crisis Key Updates Q1’27 Base Business performance (₹ Million) The QoQ performance for the Base business remained flat, however the business delivered Revenue, Gross margin and EBITDA growth of 24%, 9% and 8% YoY respectively Particulars Q1’27 Q4’26 QoQ% Q1’26 YoY% in Q1’27 underscoring the resilient operating platform. Revenue 3,077 3,070 - 2,487 24% Gross margins* 1,580 1,648 -4% 1,446 9% The Base business maintained strong profitability, delivering ~51% gross margin and ~24% EBITDA margin inspite of the raw material availability challenges and inflationary Gross margins % 51.3% 53.7% (235 bps) 58.1% (675 bps) pressures on select raw materials and solvents on account of the ongoing West Asia crisis. EBITDA 722 796 -9% 670 8% EBITDA Margins % 23.5% 25.9% (244 bps) 26.9% (348 bps) The healthy margin profile for our Base business (~51% GM / ~24% EBITDA) is a reflection of the resilience of our business model, continued focus on operational excellence and disciplined execution. Regulated markets continue to contribute 75%+ of revenues on account of healthy product mix. *Gross margins are calculated after S&D cost. Base business is excluding commodity Ibuprofen business 4 Base Business continues to exhibit a healthy trajectory across key financial metrics Revenue Gross margins EBITDA (INR Mn) (INR Mn & %) (INR Mn & %) 3070 3077 2000 70% 1000 50% 2487 2391 2466 1500 60% 800 40% 58% 50% 600 30% 1000 53% 54% 52% 40% 400 27% 26% 20% 21% 24% 500 30% 200 19% 10% 1446 1273 1365 1648 1580 670 459 520 796 722 0 20% 0 0% Q1'26 Q2'26 Q3'26 Q4'26 Q1'27 Q1'26 Q2'26 Q3'26 Q4'26 Q1'27 Q1'26 Q2'26 Q3'26 Q4'26 Q1'27 STD LTD Net Debt * (INR Mn) Net Debt to EBITDA# 6,327 6,233 6,300 6,141 4,795 4573 4761 4995 4504 3301 1754 1472 1305 1637 1494 Q1'26 Q2'26 Q3'26 Q4'26 Q1'27 FY26 Q1'27 The Base business delivers strong year-on-year growth supported by healthy margins. The Base business maintained strong profitability, delivering ~51% gross margin and ~24% EBITDA margin Reduction in net debt resulted in lower financial leverage, strengthening the balance sheet and improving debt sustainability * represents the consolidated Net debt for the company # Net debt to EBITDA ratio for Q1’27 represents annualized numbers STD – Short term debt & LTD – Long term debt Ongoing headwinds in the commodity Ibuprofen business continue to pressure our overall margins Q1’27 Ibuprofen Business performance (₹ Million) Key Updates Particulars Q1’27 Q4’26 QoQ% Q1’26 YoY% The com [Showing first 8,000 characters — download PDF for full document]